Chardan Capital Cuts CAMP4 Therapeutics (NASDAQ:CAMP) Price Target to $6.00

CAMP4 Therapeutics (NASDAQ:CAMP) had its price objective lowered by research analysts at Chardan Capital from $6.50 to $6.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the Wireless communications provider’s stock. Chardan Capital’s price objective would indicate a potential upside of 55.84% from the company’s previous close.

CAMP has been the subject of a number of other reports. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, UBS Group set a $15.00 target price on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.71.

CAMP4 Therapeutics Stock Down 1.8%

NASDAQ CAMP opened at $3.85 on Tuesday. The stock has a market cap of $241.59 million, a P/E ratio of -1.66 and a beta of 0.27. The company’s 50-day simple moving average is $4.09 and its 200 day simple moving average is $4.30. CAMP4 Therapeutics has a twelve month low of $2.85 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Research analysts anticipate that CAMP4 Therapeutics will post -0.57 earnings per share for the current year.

Insider Activity

In other news, Director Richard Young purchased 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. The trade was a 9.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have bought 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. 21.69% of the stock is currently owned by insiders.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CAMP. Jupiter Topco LLC bought a new stake in CAMP4 Therapeutics in the second quarter valued at about $27,581,000. 5AM Venture Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $25,647,928. Trails Edge Capital Partners LP acquired a new position in CAMP4 Therapeutics during the second quarter valued at approximately $8,446,935. BlackRock Inc. bought a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $7,185,000. Finally, EcoR1 Capital LLC bought a new position in shares of CAMP4 Therapeutics during the fourth quarter worth $1,992,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes.